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Abstract
Background—Social determinants of prostate cancer survival and their relation to racial/ethnic
disparities thereof are poorly understood. We analyzed whether census tract-level socioeconomic
status (SES) at diagnosis is a prognostic factor in men with prostate cancer and helps explain
racial/ethnic disparities in survival.
Methods—We used a retrospective cohort of 833 African-American and white, non-Hispanic
men diagnosed with prostate cancer at four Chicago-area medical centers between 1986 and 1990.
Tract-level concentrated disadvantage (CD), a multi-dimensional area-based measure of SES, was
calculated for each case using 1990 U.S. census data. Its association with prostate cancer-specific
survival was measured using Cox proportional hazard models adjusted for case and tumor
characteristics, treatment, and healthcare system (private sector vs. Veterans Administration
[VA]).
Results—Tract-level CD associated with an increased risk of death from prostate cancer (highest
vs. lowest quartile, hazard ratio [HR] = 2.37, p < .0001). However, the association was observed in
the private sector and not in the VA (per 1 standard deviation [SD] increase, HR = 1.33, p < .0001
and HR = 0.93, p = .46, respectively). The multivariate HR for African Americans before and after
accounting for tract-level CD was 1.30 (p = .0036) and 0.96 (p = .82), respectively.
Conclusion—Census tract-level SES is a social determinant of prostate-specific mortality and
helps account for racial/ethnic disparities in survival. An equal-access healthcare system may
moderate this association.
Impact—This study identifies a potential pathway for minimizing disparities in prostate cancer
control. The findings need confirmation in a population-based study.
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The epidemiology of prostate cancer in the United States is characterized by disparities in
survival by race and place. African Americans have worse prostate cancer-specific survival
rates than those of Whites, Hispanics and other racial/ethnic groups (1). African Americans
also tend to present with more advanced and higher histologic grade tumors than other
racial/ethnic groups, and taking these differences into account explains some but not all of
the disparity in survival (2). Consequently, researchers have investigated biological
predisposition, lifestyle, and treatment differences as other component causes of U.S. racial/
ethnic disparities in survival (3, 4).
Geographic variation in fatal prostate cancer and tumor-level predictors of survival has also
been documented. In their analysis of U.S. prostate cancer mortality rates from 1970 through
1989, Jemal et al. identified clusters of contiguous counties with rates that were statistically
significantly higher than those in the rest of the country. Prostate cancer mortality clusters
among whites were predominantly in the northwest, whereas those among African
Americans were mainly in the southeast (5). Klassen et al. conducted a smaller area analysis
of prognostic tumor characteristics among 20,928 men diagnosed with prostate cancer in the
state of Maryland between 1992 and 1997 (6). They examined variation in tumor stage and
histologic grade at the census block-group level and were able to detect clusters of
advanced-stage and high-histologic grade tumors. Adjustment for case and block-group
social and demographical characteristics altered the pattern of clusters for both stage and
grade. The results of these studies suggest that factors associated with ‘place’ influence the
prognosis of prostate cancer. These factors could include, among other things, social
determinants of health and disease.
Social determinants of prostate cancer-specific survival and their relation to racial/ethnic
disparities are poorly understood. Area-level socioeconomic status (SES) is a plausible
prognostic factor in prostate cancer, because gradients thereof associate with inequalities in
geographical access to healthcare, individual-level insurance status, and other circumstances
that can lead to clinically important variation in cancer detection, staging, treatment, and
long-term cancer care (7–9). However, in contrast to individual-level SES, the relation
between area-level SES and racial/ethnic disparities in prostate cancer-specific survival has
been more difficult to establish (10). Race and ethnicity are often highly correlated with
aggregate measures of socioeconomic status such as mean per capita household income (11).
Furthermore, area-level SES is multidimensional, composed of poverty, housing,
employment, education, racial composition, and occupational domains (12). However,
studies of area-level SES and prostate cancer survival that incorporate multidimensional
global measures of SES are scarce (13, 14). Also, given the likely complexity of the area-
level SES and cancer survival relationship, it would be desirable to link the study design to a
conceptual framework or mechanistic model that guides the selection and analysis of the
relevant variables (15).
Therefore, the primary objective of this study was to analyze whether area-level
socioeconomic status is a prognostic factor in men diagnosed with prostate cancer using a
multidimensional global measure of area-level SES. The analysis was not focused on the
geospatial dimension of an association between area-level SES and prostate cancer-specific
survival. Rather, it was concerned with area-level of SES as a non-spatial characteristic of
the environment. The secondary objective was to determine whether an association helped
explain observed racial/ethnic disparities in prostate cancer-specific survival. We
hypothesized that the socioeconomic status of the census tract of residence at the time of a
diagnosis of prostate cancer would be an independent predictor of cancer-specific survival
after accounting for patient demographic and clinical characteristics, prognostic tumor
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parameters, first-course treatment and healthcare setting, and that this association would
help explain disparities in prostate cancer-specific survival between African American and
non-Hispanic whites. These hypotheses were tested in a retrospective cohort of men
diagnosed with prostate cancer in the Chicago area using an analysis guided by the
MacArthur Model for the Pathway from Socioeconomic Status to Health (16). In this model,
the association of race/ethnicity with health is mediated by individual-level SES,
environmental resources and constraints (e.g., neighborhood factors) and psychosocial
factors. These, in turn, influence downstream factors that are more proximal determinants of
health. These factors include access to health care, the physical environment, health
behaviors, and biologic responses that may determine the development and course of
disease.
MATERIALS AND METHODS
Cohort Selection and Baseline Variables
Cohort selection and the baseline variables collected have been described in detail
previously (17). Briefly, our cohort consisted of all African-American and non-Hispanic
white men diagnosed with adenocarcinoma of the prostate (International Classification of
Diseases, 9th revision, Clinical Modification, code 187.0) at four Chicago-area medical
centers between January 1, 1986 and December 31, 1990 (n=1163) (18). Two of the medical
centers were private university-affiliated, and two were in the Veterans Health
Administration (VA) system. Cases were identified through the tumor registry at each
facility. Data were extracted from medical records by trained medical records abstractors
blinded to the hypotheses under study. These data included case demographics, tumor
characteristics, processes of diagnosis and treatment, comorbidities at the time of diagnosis,
and follow-up information. Stage assignments were based on the American Joint Committee
on Cancer TMN (tumor, node, metastasis) staging system (19). Stage was classified as
localized (tumor confined to prostate gland or extracapsular extension without lymph node
involvement [T1b-3 any, N0, M0]; regional (tumor confined to prostate gland or
extracapsular extension with regional lymph node involvement [T1b-3 any, N1, M0] or
tumor invading adjacent structures other than seminal vesicles without distant metastases
[T4, N any, M0]); distant (tumor metastases at distant sites [T any, N any, M1]); or
unstaged. Tumor differentiation was classified as well, moderately, or poorly differentiated
per the pathologist’s report. First-course treatment was defined as any treatment directed at
the primary tumor received within 4 months of initiating therapy (20, 21). Comorbidity at
the time of diagnosis was measured using the Charlson index (22). We also created an
indicator variable for healthcare system, VA vs. the private sector. This variable reflects
access independent of the ability to pay (‘equal access’) vs. access dependent on the ability
to pay.
Multidimensional Global Measure of SES at the Census Tract Level
The measure of census tract-level SES used in this analysis was based on one derived in the
Chicago area population by Browning and Cagney (23). They examined the social context
of Chicago neighborhoods in detail using information from the 1990 U.S. decennial census.
A factor analysis of 10 variables tapping into various aspects of structural disadvantage
revealed a dimension they referred to as “concentrated disadvantage.” The measure was
dominated by high factor loadings for percentage in census tract population living below the
poverty line, unemployed, residing in a female-headed household, under age 18 years (factor
loading of 0.85 for each), and African American (factor loading of 0.60). The resulting
formula weighted each variable by its factor loading: 0.85 × (% in poverty + %unemployed
+ % in female-headed household + % age under 18 years) + 0.60 × (% African-American).
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The result has been shown to predict self-rated physical health and asthma severity in the
general Chicago population (23, 24).
In our study, we did not use percentage of African-American ethnicity to calculate tract-
level concentrated disadvantage. Firstly, the major focus of our analysis was to identify
determinants of prostate cancer survival disparities between African-American and non-
Hispanic white males in the Chicago area. Secondly, we wanted to analyze our area-based
measure of SES as an independent prognostic variable rather than a confounder, and the
concentrated disadvantage measure using the original Browning and Cagney formula was
likely highly correlated with the racial composition of the census tracts. Also, additional
analyses in our study cohort, which consisted primarily of older men with prostate cancer,
supported substituting the percentage under age 18 years with (100 - % college graduate).
Consequently, the formula we used to calculate census tract-level concentrated disadvantage
scores based on 1990 U.S. census data was a simple sum of the following: % in poverty + %
unemployed + % female-headed households + (100 - % college graduate) (25). As with the
original formula, this modified version is a multidimensional area-based measure of SES,
and it does not have an analogous value at the individual level. Therefore, the results of
analyses of its impact on the prognosis of individual patients are less susceptible to ecologic
confounding compared to those based on a single-variable aggregate measure of SES (e.g.,
percent poverty), especially in the context of the research questions being addressed in this
study (26, 27).
Vital Status and Underlying Cause of Death
Follow-up of the cohort ended on December 31, 2006, with death from prostate cancer as
the underlying cause as the primary outcome of interest. The tumor registries of the
participating medical centers served as our primary source of vital status. Each tracked vital
status through active surveillance and obtained certified copies of death certificate for all
known decedents. For known decedents for whom death certificates were available through
the registries, the underlying cause of death was determined by review of the death
certificate by an independent physician reviewer who was blinded to the hypotheses under
study. For known decedents for whom death certificate were not available through the
registries and for cases whose vitals status as of December 31, 2006 could not be verified,
we determined vital status and underlying cause of death through the National Death Index.
All causes of death were coded according to the International Classification of Diseases
using the ninth revisions for deaths occurring before 1999 and the tenth revision for deaths
occurring thereafter (28, 29) The comparability ratio for malignant neoplasms of the prostate
between the tenth and ninth is 1.0134 (30).
Exclusions
Of the 1007 cases with medical records available for review, 174 were excluded for the
following reasons: cancers were T1a-stage lesions, which are considered clinically
insignificant (n = 90); incomplete data (n = 53); and the case’s residential address at
diagnosis could not be matched to its’ corresponding census tract geocode (n = 31). This left
833 cases (320 African Americans and 513 non-Hispanic whites) for statistical analysis.
Nesting of Cases by Medical Center and by Census Tract
Our sampling frame was at the medical center level. The number of cases at each of the four
medical centers was 169, 208, 222, and 234, respectively. The 833 cases represented 562
unique census tracts. Of these census tracts, 47% contained 1 case, 26% contained 2 cases,
and the rest contained 3 to 8 cases.
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We used a 2-sample t test, analysis of variance, and chi-square analysis to compare baseline
demographic and clinical characteristics of between African American and non-Hispanic
whites and across quartiles of census tract-level concentrated disadvantage. Post-diagnosis
log-log survival distributions by quartile of concentrated disadvantage at diagnosis were
computed after accounting for case race/ethnicity (African-American vs. non-Hispanic
White), tumor differentiation (moderate and poor vs. well), tumor stage (local/region vs.
distant/unstaged), age (continuous), Charlson comorbidity score (continuous), first-course
treatment, and healthcare system (private sector vs. VA). The Wald chi-square statistic was
used to compare the resulting survival distributions across quartiles. Localized and regional-
stage cases were combined, because they would be candidates for aggressive primary
therapy. Unstaged cases were combined with distant cases because their respective survival
distributions were not significantly different (p = .61).
Cox proportional hazard models measured the association of African-American ethnicity
with prostate cancer-specific survival after sequential adjustment for tumor characteristics,
age and comorbidities, first-course treatment (surgery, radiation, diethylstilbestrol,
castration, experimental, or observation-only), concentrated disadvantage (quartiles, with the
lowest quartile as the reference category) and healthcare system. The sequence of the
adjustments was guided by the MacArthur Model. Based on this conceptual model, we
evaluated the following four statistical models:
Model 1: λ(t;Z)=λ0(t) exp(β1race/ethnicity)
Model 2: λ(t;Z)=λ0(t) exp(β1race/ethnicity + β2stage + β3differentiation + β4age +
β5Charlson score + β6first-course treatment + Interactions)
Model 3: λ(t;Z)=λ0(t) exp(β1race/ethnicity + β2stage + β3differentiation + β4age +
β5Charlson score + β6first-course treatment + β7concentrated disadvantage quartiles +
Interactions).
Model 4: λ(t;Z)=λ0(t) exp(β1race/ethnicity + β2stage + β3differentiation + β4age +
β5Charlson score + β6first-course treatment + β7concentrated disadvantage quartiles +
β8healthcare system + Interactions)
where Z denotes the variables incorporated into each model.
Model 1 estimated the crude hazard of prostate cancer-specific mortality for African
Americans vs. non-Hispanic Whites. Model 2 estimated the multivariate hazard of prostate
cancer-specific mortality for African Americans vs. non-Hispanic Whites as function of
prognostic tumor parameters, first-course treatment, and competing hazards of death from
other causes. Model 3 evaluated the multivariate hazard of prostate cancer-specific mortality
for African Americans vs. non-Hispanic Whites after accounting for census tract-level
concentrated disadvantage. Model 4 then takes healthcare system into account. Using
product terms, we tested for interaction between independent variables and incorporated
statistically significant ones where applicable. Models 2 thru 4 were also adjusted for
diagnosis year, and deaths from causes other than prostate cancer were analyzed as censored
observations. We used Schoenfield residuals and time-dependent coefficients to test the
proportional hazards assumption in each model evaluated (31). No violations of the
proportional hazards assumptions were observed (p = .12 to .83). Regression diagnostics
were also performed on all multivariate models to detect any evidence of collinearity among
the independent variables. Collinearity problems occur when any one independent variable
reflects a near linear combination of one or more other independent variables in the model.
Indicators of potential problems in this regard include a variance inflation factor greater than
10 and a condition index greater than 30, especially when the proportion of variance in the
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parameter estimate was greater than 0.5 (32). The statistical analyses were performed with
the statistical package SAS version 9.2 (SAS Institute, Inc. Cary, NC) (33). Cox
proportional hazards were analyzed using the ‘PHREG’ procedure with the
‘COVSANDWICH’ option to account for the nesting of cases by medical center. In this
option, the standard errors for the model parameters are computed using the robust
‘sandwich’ variance estimator of Lin and Wei (34). We repeated the analysis to account for
the nesting of cases by census tract, but results were essentially the same as those without
the sandwich variance estimate.
RESULTS
Baseline characteristics and mortality outcomes of the cohort are summarized in Table 1.
Cases were followed on average for 8.6 years, with an overall mortality rate of 75.5 percent.
Approximately forty percent of the deaths were due to prostate cancer (n=256). African
Americans were significantly more likely than their non-Hispanic white counterparts to be
diagnosed with advanced stage disease (p < .0001) and to die of prostate cancer (p = .0064).
At the time of diagnosis, African Americans resided in census tracts with higher
concentrated disadvantage scores compared with those of non-Hispanic whites (mean =
124.4 vs. 80.8, respectively, p < .0001). This was reflected in the increasing numbers of
African-Americans with increasing quartile of concentrated disadvantage (p < .0001). The
likelihood of being diagnosed at an advanced tumor stage also increased with increasing
quartile of concentration disadvantage (p = .0058). The probability of death due to prostate
cancer increased as well, but the trend did not reach statistical significance (overall, p = .24
and highest vs. lowest quartile, p = .052).
Figure 1 shows prostate cancer-specific survival by quartile of census tract-level
concentrated disadvantage at diagnosis after adjustment for race/ethnicity, age, tumor
characteristics, first-course treatment, Charlson comorbidity score, and healthcare system. A
statistically significant trend in survival across quartiles was observed (p-trend = .006). The
survival distributions began to diverge by the second year of follow-up, with the greatest
contrast being between the first and fourth quartiles. The survival distributions in the second
and third quartiles of concentrated disadvantaged appeared to be similar, but these too
diverged after the eighth year of follow-up.
Table 2 presents the results of Cox proportional hazards models that measure the association
between race/ethnicity and prostate cancer-specific survival before and after sequential
adjustment for baseline clinical characteristics, census tract-level concentrated disadvantage,
and healthcare system. Initially, African Americans were significantly more likely to die of
prostate cancer relative to non-Hispanic whites (model 1 - hazard ratio [HR] = 1.58, p = .
0051). Moreover, the excess risk among African Americans persisted after accounting for
prognostic tumor parameters, age, comorbidity, and first-course treatment (model 2 -
multivariate HR = 1.30, p = .0036). After accounting for census tract-level concentrated
disadvantage at diagnosis (model 3), the association between African-American ethnicity
and prostate cancer-specific survival disappeared (multivariate HR = 0.98, p = .82); at the
same time, an inverse association between concentrated disadvantage and survival was
observed (highest vs. lowest quartile, multivariate HR = 1.77, p = .0043, p trend = .0029).
Regression diagnostics did not detect any potential collinearity of concern between race/
ethnicity and concentrated disadvantage or any other combination of independent variables
in the model (proportion of variance 2.1 × 10−7 to 0.58, condition index 1 to 3.6, and
variance inflation factor 1.1 to 2.8). The final model incorporates healthcare system (VA vs.
private sector). The inverse association between census tract-level concentrated
disadvantage and prostate cancer-specific survival persisted (highest vs. lowest quartile,
multivariate HR = 2.37, p < .0001, p trend < .0001). Furthermore, a statistically significant
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interaction with healthcare setting was observed (p = .0043). Other statistically significant
interactions were not detected.
Figure 2 illustrates the difference in the association between census tract-level concentrated
disadvantage and prostate cancer-specific survival in cases diagnosed and treated in the
private sector versus those in the VA healthcare system. Census tract-level concentrated
disadvantage was risk factor for death due to prostate cancer in the private sector (per 1
standard deviation [SD] increase, multivariate HR = 1.33, p < .0001) but not in the VA
system (per 1 SD increase, multivariate HR = 0.93, p = .46). Furthermore, this modification
of the association between tract-level concentrated disadvantage and prostate cancer-specific
survival by healthcare system was evident for both African Americans and non-Hispanic
whites.
DISCUSSION
In this study, census tract-level socioeconomic status was an independent predictor of in
prostate cancer-specific survival based on a multi-dimensional measure of tract-level SES
and helped account for racial disparities in survival. Two other studies have analyzed the
impact of area-level SES on prostate cancer-specific survival in the United States using
multidimensional measures of area-level SES. Robbins et al. evaluated whether differences
in prostate cancer survival between 122,374 black men and non-Hispanic white men
diagnosed with prostate cancer in the state of California between 1995 and 2004 were
reduced or eliminated after accounting for differences in age, stage, treatment, grade,
diagnosis year, and block-group SES (13). The cases were identified through the state’s
population-based cancer registry data, and block group level SES was characterized using an
index that incorporated seven 1990 U.S. census indicators of income, housing, education,
and occupation to create a composite SES score (35) After simultaneous adjustment for the
other prognostic factors under study, higher block group-level SES scores associated with a
significantly lower risk of death from prostate cancer in both black and non-Hispanic white
men (highest vs. lowest quintile, multivariate HR = 0.77 [95% CI = 0.60 to 0.99] and 0.66
[95% CI = 0.60 to 0.72], respectively). White al. conducted as similar population-based
analysis in a multi-ethnic cohort of 87,449 men diagnosed with prostate cancer in the state
of Texas between 1995 and 2002 (14). The authors measured block group-level SES using a
principal component analysis-derived composite variable that incorporated median
household income, percentage of men living below poverty, percentage with a college
education, percentage with a management/professional occupation, and median home value
based on the 2000 US census (36). After simultaneous adjustment for age, tumor stage,
grade, diagnosis year, and rural residence, block group-level SES was significantly
associated with prostate cancer-specific survival (lowest vs. highest quintile, multivariate
HR = 1.36 [95% CI = 1.36 to 1.49]). Our results are consistent with the findings or these two
studies.
White et al. also explored the impact of area-level SES and rural residence on racial/ethnic
differences in prostate cancer-specific survival by comparing the hazard ratios for race/
ethnicity across three models (table 5 in their paper). Model 1 consisted only of race/
ethnicity only (non-Hispanic black, Hispanic, and Asian/Pacific Islander vs. non-Hispanic
white); model 2 added age, stage, grade, and diagnosis year; and model 3 added block group
SES and rural residence to the variables in model 2. The hazard ratio (95% CI) for non-
Hispanic blacks vs. non-Hispanic whites in these models were 2.01 (1.89–2.17), 1.84 (1.71–
1.97), and 1.70 (1.58–1.83), respectively. The authors did not evaluate the influence of SES
and rural residence separately. However, the sequence of adjustments and trend in the black-
white disparity in prostate cancer survival are similar to that in our study.
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The mechanisms underlying the association of area-level SES with prostate cancer-specific
survival in these studies are not clear. However, in our study, the absence of the association
in the VA suggests that healthcare system-related factors after diagnosis may be responsible.
In fact, our findings suggest that a diagnosis of prostate cancer in an equal-access system
protects against the adverse effects of area-based socioeconomic gradients on prostate
cancer survival. These gradients may also associate with inappropriate variation in care after
treatment, including the intensity of surveillance, timeliness and nature of responses to
changes in cancer status, and the detection and treatment of new health problems.
Unfortunately, data on these relationships are scarce and, thus, are a critical gap in our
understanding of the prognostic impact of area-level SES on cancer-specific survival not
only in prostate cancer but in cancer in general. Finally, area-level SES is inversely
associated with allostatic load, which has been conceptualized by McEwen and Seeman as
the cumulative physiologic burden imposed by stress (37–39). Measures of allostatic load
typically reflect the activity of multiple health regulatory pathways such as immunity/
inflammation, energy balance and others implicated in carcinogenesis and proposed as
targets for cancer control (40–43). Consequently, area-level SES may have a biological
influence on the course of prostate cancer either at the tumor level or through the host’s
response to the disease and its treatment.
Our study has several important limitations. The cohort was derived from a case series at
four Chicago area medical centers rather than a population-based sampling frame. As a
result, the choice of medical centers could have exaggerated differences in census tract-level
SES and survival between our African-American and non-Hispanic white case and between
medical centers. Of note, our age-adjusted prostate cancer mortality hazard ratio for African
Americans vs. non-Hispanic whites was 1.56 (95% CI = 1.14 to 2.14), which is comparable
to that reported by others (1, 13, 14). Also, we did not account for changes in tract-level SES
between diagnosis and end of follow-up or patterns of care after first-course therapy and
other post-treatment factors. Consequently, we were not able use our data to further clarify
potential mechanisms involved the association that we observed between census tract-level
SES and prostate cancer-specific survival. Finally, the men in our study were largely
diagnosed just prior to the introduction of the prostate specific antigen (PSA) test for
screening and early detection. Consequently, our cohort had a higher proportion of men who
were diagnosed at an advanced-stage than would be expected in the PSA era.
In conclusion, much work remains on identifying the social determinants of disparities in
prostate cancer prognosis. In our study, the socioeconomic status of the census tract of
residence at diagnosis predicted prostate cancer-specific survival independent of age, race/
ethnicity, prognostic tumor parameters, comorbidities, and initial treatment. Tract-level SES
also helped account for differences in cancer-specific survival observed between African
Americans and non-Hispanic whites. Furthermore, being diagnosed in an equal access
healthcare system mitigated the influence of census tract-level SES on survival. Healthcare
system factors, patterns of cancer care, and tumor/host biology after initial treatment are
plausible mediators of the association. Unfortunately, data on these and other potential
mediating relationships are scarce. Future research should focus on identifying the
underlying mechanisms for the association of census tract-level SES with prostate cancer-
specific survival. The results of this study are consistent with the view that minimizing
differences in healthcare access is a pathway to minimizing disparities in cancer control
(44). However, our results need to be corroborated using a population-based study design
that is guided by an appropriate conceptual framework for identifying social disparities in
prostate cancer.
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Log-log plot of prostate cancer-specific survival for 833 men diagnosed with prostate cancer
between 1986 and 1990 stratified by quartile of census tract-level concentrated disadvantage
at diagnosis: Chicago Metropolitan Area (p-trend = 0.006). The individual survival curves
are adjusted for race/ethnicity, age, tumor characteristics, first-course treatment, Charlson
comorbidity score, and healthcare system (private sector vs. Veterans Health
Administration), and treatment date.
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Multivariate hazard ratios for prostate cancer-specific mortality per 1 standard deviation
increase in census tract-level concentrated disadvantage for 833 men diagnosed with
prostate cancer between 1986 and 1990, private sector vs. Veterans Health Administration
healthcare system: Chicago area. Hazard ratios are adjusted for age, tumor characteristics,
first-course treatment, Charlson comorbidity score, and in the case for all patients in either
healthcare setting, race/ethnicity. Note: SD = standard deviation, CD = concentrated
disadvantage, AA = African Americans, WNH = White, Non-Hispanic, and CI = confidence
interval.
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